News | April 30, 2026
Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout
The agreement could rise to $900 million if key commercial milestones are met
The agreement could rise to $900 million if key commercial milestones are met
Health innovations are viewed more positively than food and agricultural technologies
Company to highlight science-backed actives, nature-powered ingredients, and its new “Natural by Barentz” private label platform in Barcelona
SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Subscribe To Our Newsletter & Stay Updated
